Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | EIF4A1 | P60842 | 14/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | ABHD10 | Q9NUJ1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20006330 | 0.80 | CYP3A4 (0.48) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL18862683 | 0.77 | EIF4A1 (0.46) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL29531658 | 0.77 | EIF4A1 (0.49) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL18836478 | 0.77 | EIF4A1 (0.49) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL17414041 | 0.77 | EIF4A1 (0.49) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL24180245 | 0.70 | CYP3A4 (0.45) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL20006092 | 0.66 | EIF4A1 (0.51) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL20006140 | 0.66 | CYP3A4 (0.49) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL17396544 | 0.66 | CYP3A4 (0.47) | MEN1KMT2AATMNPSR1EIF4A1 | |
| SCHEMBL24180208 | 0.65 | ABHD10 (0.38) | MEN1KMT2AATMNPSR1EIF4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519125-B2 | Flavagline derivatives | PIERRE FABRE MEDICAMENT (FR) | 2019-12-31 | — | — | US | disclosed |
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086729-A1 | FLAVAGLINE DERIVATIVES | GCG, GCGR, KRAS | MEN1 462/4885KMT2A 2790/4885ATM 4306/4885 |
| US-10519125-B2 | Flavagline derivatives | GCG, GCGR, KRAS | MEN1 462/4885KMT2A 2790/4885ATM 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.